{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:20Z","timestamp":1792099580075,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>There are limited data on treatment patterns, adverse events (AEs), and economic burden in younger, commercially insured patients treated for mantle cell lymphoma (MCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with\u00a0\u22651 treatment for MCL between 1 November 2013\u201031 December 2017 were identified from IQVIA Real\u2010World Data Adjudicated Claims\u2010US; index date was first treatment. Patients carried \u22651 MCL diagnosis, were newly treated, and were enrolled continuously for \u226512\u00a0months prior to and \u226530\u00a0days following index. Patients receiving the four most common MCL regimens were included. Measures included frequency of incident AEs, resource use, and costs overall and by number of AEs. Adjusted logistic regression and generalized linear modeling evaluated risk of hospitalization and all\u2010cause costs per patient per month (PPPM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two thousand five hundred and nine treated patients had a drug\u2010specific code and were classified to a specific treatment regimen. Of those patients, 1785 patients received at least one of the four most commonly used MCL regimens (R\u2010CHOP, rituximab monotherapy, B\u2010R, and ibrutinib) at some point over follow\u2010up (median 23\u00a0months). R\u2010CHOP was the most common regimen observed in the first line (26%), followed by rituximab monotherapy (19%), B\u2010R (15%), and ibrutinib (5%). The median age was 57\u00a0years; median Charlson Comorbidity Index was 0. Among patients receiving the four most common regimens, 63% of patients experienced \u22651 incident AE (R\u2010CHOP 77%, B\u2010R 58%, and ibrutinib 52%). An increasing number of incident AEs was associated with increased hospitalization risk (odds ratio\u00a0=\u00a02.4; 95% Confidence Interval [CI] 2.1\u20102.7) and increased mean costs PPPM (cost ratio\u00a0=\u00a01.1; 95% CI 1.1\u20101.2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This is the largest study describing treatment patterns and clinical and economic impact of MCL treatment. The most common regimens were R\u2010CHOP, rituximab monotherapy, B\u2010R, and ibrutinib. The majority of treated patients experienced at least one incident AE, with hospitalization risk and all\u2010cause costs increasing as the number of AEs increased.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.2559","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T06:45:17Z","timestamp":1570603517000},"page":"7174-7185","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States"],"prefix":"10.1002","volume":"8","author":[{"given":"Shaum M.","family":"Kabadi","sequence":"first","affiliation":[{"name":"AstraZeneca Gaithersburg MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Near","sequence":"additional","affiliation":[{"name":"IQVIA Falls Church VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Wada","sequence":"additional","affiliation":[{"name":"IQVIA Falls Church VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakkarin","family":"Burudpakdee","sequence":"additional","affiliation":[{"name":"IQVIA Falls Church VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24797"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0556-x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.008"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.649476"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_6_13_1","unstructured":"FDA.Ibrutinib Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205552s020lbl.pdf. Accessed March 20 2018."},{"key":"e_1_2_6_14_1","unstructured":"FDA.Acalabrutinib prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf. Accessed June 5 2018."},{"key":"e_1_2_6_15_1","unstructured":"Lenalidomide Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021880s055lbl.pdf. Accessed October 25 2018."},{"key":"e_1_2_6_16_1","unstructured":"Velcade Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021602s043lbl.pdf. Accessed October 25 2018."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1509320"},{"issue":"19","key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1158\/1538-7445.AM2014-4139","article-title":"Abstract 4139: healthcare resource utilization (HRU) in treated mantle cell lymphoma (MCL) patients","volume":"74","author":"Kozma CM","year":"2014","journal-title":"Can Res"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001723"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_6_22_1","unstructured":"Consumer Price Index.https:\/\/www.bls.gov\/cpi\/."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22367"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977"},{"issue":"9","key":"e_1_2_6_25_1","first-page":"590","article-title":"Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma","volume":"36","author":"Fowler NH","year":"2011","journal-title":"Pharm Ther"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11304"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"e_1_2_6_29_1","unstructured":"SharmanJB\u2010SJ ClarkJ MantleKS.Cell lymphoma treatment patterns and outcomes. 59th American Society for Hematology Annual Meeting Atlanta GA.2017."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:05:18Z","timestamp":1694174718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/cam4.2559"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2559","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]},"assertion":[{"value":"2018-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}